Emily, most people with concerns about the C****-** v*****e are legitimately focused on the immediate risks, i.e. pain, swelling, thrombocytopenia, cardiac arrest, anaphylaxis and Bell’s palsy. Given the large number of v*****e shots administered, most feel the risk of the v*****e is worth the reward.
But there are two 800 lb elephants in the room, that very few people are addressing, which are
1. Other allergic responses to autoimmunity, sepsis and organ failure (immune escape), and
2. The use of tumorigenic and tumor-derived cell lines in the creation of the v*****e.
As to #1 above, here are some of the "issues" that would concern me:
“In light of the information discussed above about the cross-reactivity of the SARS-CoV-2 proteins with human tissues and the possibility of either inducing autoimmunity, exacerbating already unhealthy conditions, or otherwise resulting in unforeseen consequences, it would only be prudent to do more extensive research regarding the autoimmune-inducing capacity of the SARS-CoV-2 antigens.”
“Our present study used human monoclonal antibodies against SARS-CoV-2 proteins, and we found reactivity with 28 out of 55 tested human antigens.”
“The third important question to consider is whether cross-reactivity between C****-** and human tissue can lead to autoimmune disease development either from the infection or directly from v******tion. Determining this can be an enormous task because the development of most autoimmune diseases may take 3 to 18 years (7). Segal and Shoenfeld have raised concerns for v*****e-induced autoimmunity by citing examples of how previous v******tions have induced cross-reactive autoimmunity in susceptible subgroups.
They cite specific examples of how v*****e-induced cross-reactivity has led to the onset of systemic lupus erythematous, demyelinating autoimmune diseases, narcolepsy, and postural orthostatic tachycardia syndrome.”Tissues Affected
The reasoning is that immune response against the v***l antigens following infection or v******tion can cross-react with human tissue antigens that share sequence homology with the v***s, resulting in autoimmune reactivity, possibly followed by outright autoimmune disease (5, 10, 19, 24, 25). Some support for this proposed mechanism for the induction of autoimmunity was presented by Lyons-Weiler (5) when he compared immunogenic epitopes of SARS-CoV-2 to human proteins and found a high degree of homology with various tissues. These included heart muscle, skeletal muscle, thyroid gland, kidney, brain, pituitary gland, testes, lung, blood, gastrointestinal tract, eye, liver, bone marrow, adipose tissue, skin, and many ubiquitous proteins.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246018/https://www.frontiersin.org/articles/10.3389/fimmu.2020.617089/full As to #2 above:
"Immortalized Cell line - The cell line in which Janssen grows its adenov***s vector is a human embryonic cell line called PER.C6. The retinal tissue that launched the cell line was obtained following the elective a******n of a healthy, 18-week-old fetus. The AstraZeneca-Oxford C***D v*****e uses a different human embryonic cell line called HEK293T to propagate its adenov***s."
To produce a continuous cell line of this type — what is called an “immortalized” cell line — scientists must artificially manipulate the original cells, which otherwise would have finite lifespans. This is accomplished by introducing chemical exposures or rendering them cancerous. Because this manipulation introduces genetic changes into the cells, “cell populations and cellular mechanisms are altered.”
A senior FDA official warned over two decades ago about the inherent risks of using continuous cell lines for v*****e development, noting that such cell lines, “by definition” have a******lities, and worriedly acknowledging their “potential for growing tumors in laboratory animals.”An FDA document published in late 2020 shows that these issues are far from resolved; explicitly referring to cell lines such as PER.C6 and HEK293T, the FDA author states:
“The use of tumorigenic and tumor-derived cells is a major safety concern” and observes that the cell lines contain “latent” or “quiet” threats that “might become active under v*****e manufacturing conditions.”The fact sheet for healthcare providers administering the J&J C***D v*****e specifies that each dose of v*****e “may … contain residual amounts of host cell proteins … and/or host cell DNA,” but the simplified fact sheet intended for v*****e recipients and their caregivers does not.
That means that unless v*****e recipients seek out the healthcare provider fact sheet, they’ll be unaware of this potentially crucial piece of information.
"The Italian v*****e research and advocacy organization, Corvelva, which has conducted detailed studies of DNA from aborted fetal cell lines in v*****es, warns that such DNA is a******l and potentially tumor-causing. Corvelva concludes that v*****es of this type “should be considered defective and potentially dangerous to human health.”
"Along with a variety of other inactive ingredients, the J&J C***D v*****e also includes polysorbate-80, a stabilizer that studies have shown capable of t***sporting other substances across the blood-brain barrier."
The lack of long term safety trials should put both of these issues in the forefront of this discussion. This will turn out to be the largest v*****e human trial ever.
Emily, most people with concerns about the C****-*... (